Najia Khurram

Aug 27, 2024 | jamanetwork.com | Robert Hamilton |Julian Chavarriaga |Cindy Y Lau |Najia Khurram

Key PointsQuestion  Is 5-alpha-reductase-inhibitor (5-ARI) use prior to prostate cancer (PCa) diagnosis associated with overall mortality or PCa-specific mortality? Findings  In this cohort study of 19 938 patients with PCa who had long-term follow-up and detailed pathological information, prediagnostic 5-ARI use was not associated with overall mortality or PCa mortality. Meaning  These findings suggest that 5-ARIs are safe to use for benign prostatic hyperplasia and PCa chemoprevention.